联合用药治疗耐碳青霉烯铜绿假单胞菌感染的研究进展

杨德青,倪文涛,江学维,王瑾,王睿,于白雪

中国药学杂志 ›› 2017, Vol. 52 ›› Issue (14) : 1208-1211.

PDF(1034 KB)
PDF(1034 KB)
中国药学杂志 ›› 2017, Vol. 52 ›› Issue (14) : 1208-1211. DOI: 10.11669/cpj.2017.14.003
综述

联合用药治疗耐碳青霉烯铜绿假单胞菌感染的研究进展

  • 杨德青1,2a,倪文涛2b,江学维2a,王瑾2a,王睿2a,于白雪2a
作者信息 +

Progress in Combination Therapy to Infection of Carbapenem-Resistant Pseudomonas aeruginosa

  • YANG De-qing1,2a, NI Wen-tao2b, JIANG Xue-wei2a, WANG Jin2a, WANG Rui2a, YU Bai-xue2a
Author information +
文章历史 +

摘要

耐碳青霉烯类铜绿假单胞菌(carbapenem-resistant Pseudomonas aeruginosa,CRPA)已有在医院院内爆发流行的趋势,治疗失败率和病死率高,有效的单用抗菌药物非常有限,往往建议联合用药治疗CRPA感染。笔者就联合用药治疗CRPA感染的体内外效应及临床研究方面进行综述,以全面掌握联合用药治疗CRPA感染的研究进展,为临床合理使用联合方案治疗CRPA感染提供一定的试验基础。

Abstract

The outbreak of carbapenem-resistant Pseudomonas aeruginosa has been continuously reported in hospitals worldwide. The infection caused by carbapenem-resistant Pseudomonas aeruginosa increased the therapy failure and mortality, the effective antibiotics against carbapenem-resistant Pseudomonas aeruginosa are limited, and combination therapy is often recommended to treat CRPA infection. To fully master the advance on combination therapy of CRPA infection, and provide a theoretical basis for the rational use of the combination therapy, this article reviewed the synergistic effect in vitro or in vivo and clinical study of antimicrobial agents treating CRPA infection.

关键词

耐碳青霉烯铜绿假单胞菌 / 联合效应 / 联合用药 / 治疗

Key words

carbapenem-resistant Pseudomonas aeruginosa / synergistic effect / combination therapy / treatment

引用本文

导出引用
杨德青,倪文涛,江学维,王瑾,王睿,于白雪. 联合用药治疗耐碳青霉烯铜绿假单胞菌感染的研究进展[J]. 中国药学杂志, 2017, 52(14): 1208-1211 https://doi.org/10.11669/cpj.2017.14.003
YANG De-qing, NI Wen-tao, JIANG Xue-wei, WANG Jin, WANG Rui, YU Bai-xue. Progress in Combination Therapy to Infection of Carbapenem-Resistant Pseudomonas aeruginosa[J]. Chinese Pharmaceutical Journal, 2017, 52(14): 1208-1211 https://doi.org/10.11669/cpj.2017.14.003
中图分类号: R969.3   

参考文献

[1] MORALES E, COTS F, SALA M, et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res, 2012, 12(1): 122.
[2] RAI S, DAS D, NIRANJAN D K, et al. Carriage prevalence of carbapenem-resistant Enterobacteriaceae in stool samples: a surveillance study. Australas Med J, 2014, 7(2): 64-67.
[3] LESHO E, CHUKWUMA U, SPARKS M, et al. Anatomic, geographic, and taxon-specific relative risks of carbapenem resistance in the Health Care System of the US. Department of Defense. J Clin Microbiol,2016, 54(6):1546-1551.
[4] RODLOFF A C, DOWZICKY M J. Antimicrobial susceptibility among european gram-negative and gram-positive isolates collected as part of the tigecycline evaluation and surveillance trial(2004-2014) . Chemotherapy, 2016, 62(1):1-11.
[5] LABARCA J A, SALLES M J, SEAS C, et al. Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii in the nosocomial setting in Latin America . Crit Rev Microbiol, 2016, 42(2): 276-292.
[6] KIRATISIN P, CHONGTHALEONG A, TAN T Y, et al. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study . Int J Antimicrob Agents, 2012, 39(4): 311-316.
[7] Committee of Experts on Rational Drug Use, National Health and Family Planning Commission of the P.R.China; China Antimicrobial Resistance Surveillance System Surveillance Report of bacterial resistance in 2015. Chin Lic Pharm(中国执业药师), 2016, 13(3): 3-8.
[8] CORNAGLIA G, MAZZARIOL A, LAURETTI L, et al. Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-betalactamase . Clin Infect Dis, 2000, 31(5): 1119-1125.
[9] TSAKRIS A, POURNARAS S, WOODFORD N, et al. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece . J Clin Microbiol, 2000, 38(3): 1290-1292.
HUH K, KIM J, CHO S Y, et al. Continuous increase of the antimicrobial resistance among gram-negative pathogens ausing bacteremia: a nationwide surveillance study by the Korean Network for Study on Infectious Diseases(KONSID) . Diagn Microbiol Infect Dis, 2013,76(4):477-482.
YAHA D, FARBMAN L, LEIBOVICI L, et al. Colistin: new lessons on an old antibiotic . Clin Microbiol Infect, 2012,18(1):18-29.
RAO G G, LY N S, HAAS C E, et al. New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease . Antimicrob Agents Chemother, 2014,58(3):1381-1388.
National Health and Family Planning Commission of the P.R. China. Resistant Gram-Negative Bacteria Infection Diagnostic Manual(耐药革兰阴性菌感染诊疗手册). Vol 1. Beijing:People′s Medical Publishing House Press, 2015:20.
DI X, WANG R, LIU B, et al. In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa . J Antibiot(Tokyo), 2015, 68(9):551-555.
LOPEZ-FABAL F, CULEBRAS E, BONILLA I, et al. In vitro activities of colistin combinations against Pseudomonas aeruginosa isolated from the intensive care unit. Rev Esp Quimioter, 2008, 21(3):189-193.
AOKI N, TATEDA K, KIKUCHI Y, et al. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa . J Antimicrob Chemother,2009, 63(3):534-542.
NIU H, LIANG B B, ZHANG X, et al. In vitro activity of colistin combination with biapenem against carbopenems-resistant Pseudomonas aeruginosa . Chin J Clin Pharm (中国临床药理学杂志), 2015, 31(24): 2437-2439.
HU Y F,LIU C P,WANG N Y, et al.In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem againstmultidrug-resistant clinical isolates of Pseudomonas aeruginosa. BMC Infect Dis, 2016,16(1):444.
NAGAOKA R, IKAWA K, ONODERA M,et al. In vitro combined effects of double antibacterial drugs against multidrug-resistant Pseudomonas aeruginosa isolates: comparison among combinations of colistin, arbekacin, aztreonam, rifampicin and piperacillin . Jpn J Antibiot, 2014,67(3):167-174.
YE M, YANG X M,WANG G, et al. The analysis of zymogenic state against Carbapenems-resistant Pseudomonas aeruginosa using a susceptibility test . Mili Med J South Chin(东南国防医药), 2011, 13(2): 135-137.
IGBINOSA E O, ODJADJARE E E, IGBINOSA I H, et al. Antibiotic synergy interaction against multidrug-resistant Pseudomonas aeruginosa isolated from an abattoireffluent environment. Scien World J, 2012, 2012(5):308034.
SANTOS D A, NASCIMENTO M M, VITALI L H, et al. In vitro activity of antimicrobial combinations against multidrug-resistant Pseudomonas aeruginosa . Rev Soc Bras Med Trop,2013,6(3):299-303.
PENG J Q, ZENG C J, LI G N, et al. Evaluation of combined effects of ceforperzazone/sulbactaman amikamcin againsts trains of imipenem-resistant Pseudomonas aeruginosa. Int J Lab Med(国际检验医学杂志), 2015, 36(13): 1902-1904.
XU Y P, CAO J R, LI L Z, et al. Combination antimicrobial susceptibility test on 43 multi-drug-resistant isolates of Pseudomonas aeruginosa . Chin J Nosocomiol(中华医院感染学杂志), 2007, 17(2): 210-212.
KUNAKONVICHAYA B, THIRAPANMETHEE K, KHUNTAYAPORN P, et al. Synergistic effects of fosfomycin and carbapenems against carbapenem-resistant Pseudomonas aeruginosa clinical isolates. Int J Antimicrob Agents, 2015, 45(5): 556-557.
HE W, KANIGA K, LYNCH A S, et al. In vitro E-test synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the E-test method . Diagn Microbiol Infect Dis, 2012, 74(4): 417-419.
LEE H, ROH K H, HONG S G, et al. In vitro synergistic effects of antimicrobial combinations on extensively drug-resistant pseudomonasaeruginosa and Acinetobacter baumannii isolates . Ann Lab Med, 2016,6(2):138-144.
ERDEM I, KAYNAR-TASCIOGLU J, KAYA B, et al. The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacinagainst multidrug-resistant Pseudomonaseruginosa strains . Int J Antimicrob Agents, 2015, 45(5):556-557.
KUNAKONVICHAYA B, THIRAPANMETHEE K, KHUNTAYAPORN P, et al. Synergistic effects of fosfomycin and carbapenems against carbapenem-resistant Pseudomonas aeruginosa clinical isolates . Int J Antimicrob Agents, 2015, 45(5):556-557.
GOMEZ-GARCES J L, GIL-ROMERO Y, SANZ-RODRIGUEZ N, et al. In vitro activity of fosfomycin, alone or in combination, against clinical isolates of carbapenem resistant Pseudomonas aeruginosa . EnfermInfecc Microbiol Clin, 2016, 34(4): 228-231.
XIONG Y Q, POTEL G, CAILLON J, et al. Comparative efficacies of ciprofloxacin and pefloxacin alone or in combination with fosfomycin in experimentalendocarditis induced by multidrug-susceptible and -resistant Pseudomonas aeruginosa . Antimicrob Agents Chemother, 1995,39(2):496-496.
KANELLAKOPOULOU K, SARAFIS P, GALANI I,et al. In vitro synergism of beta-lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of Pseudomonas aeruginosa . Int J Antimicrob Agents, 2008, 32(1):33-39.
ERENM I, KUCUKERCAN M, CERAN N. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam,or meropenem with ciprofloxacinagainst multidrug-resistant Pseudomonas aeruginosa strains . Chemotherapy, 2003, 49(6):294-297.
WEN Y K, CAO M, ZHOU, et al.Combined drug sensitivity test of carbapenem-resistant Pseudomonasaeruginosa in vitro . Chin J Antibiot(中国抗生素杂志), 2012, 37(7):536-538.
DI X Z, BAI N, TANG M J, et al. Combined effect of fosfomycin and polymyxin E against carbapenem-Pseudomonas aeruginosa. Chinese Pharmaceutical Association Drug Clinical Evaluation ResearchSpecialized Committee, 2015.
GAN X D. Clinical efficacy of Azithromycin combined with ciprofloxacin in the treatment of Pseudomonas aeruginosa infection in patients with Pseudomonas aeruginosa . Chin J Clin Rational Drug Use(临床合理用药), 2014, 7(6): 57-58.
XIA C, XIE X H, WANG L L, et al. Effects of azithromycin on MexAb-OprM efflux pump and antibiotic resistance in Pseudomonas aeruginosa infection . J Huazhong Univ Sci Technol(华中科技大学学报), 2012, 10(3) : 69-75.
ZHANG X C, QIN Y F, BAO C M, et al. Azithromycin combined with ciprofloxacin in treament of carbarpenem-resistant Pseudomonas aeruginosainfection . Chin Hosp Pharm J(中国医院药学杂志), 2013, 33(16): 1341-1343.
LIU Q M, ZHANG Z, LIAO H. Clinical studies of ciprofloxacin and azithromycin for trentment of carbapenem-resistant Pseudomonas aeruginosa infection . Chin J Med Guide(中国医药导刊), 2015, 17(6): 591-593.
HOFFMAN N, LEE B, HENTZER M, et al. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob Agents Chemother, 2007, 51(10): 3677-3687.
JIAN L J. Intervention effect and mechanism of azithromycin on the biofilm and virulence factors of Pseudomonas aeruginosa . Nanning: Guangxi Medical University, 2011.
LIANG T, LIU L, SUN Z Y. Analysis of clinical efficacy of combining use of azithromycin and ciprofloxacin to cure carbapenem resistant Pseudomonas aeruginosa infections . Chin J Nosocomiol(中华医院感染学杂志), 2014, 24(11): 2680-2683.
WANG L M,YAO M, HAN M, et al. Management of Carbapenem-resistant Pseudomonas Aeruginosa-induced Infection. Chinese Pharmaceutical Association:China Pharmaceutical Conference and the thirteenth Chinese pharmacist week proceedings, Beijing:2013:2601-2607.
APISARNTHANARAK A, MUNDY L M. Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitoryconcentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin . Int J Antimicrob Agents, 2012, 39(3): 271-272.
CHEN Y F, CAO W S. Review on the clinical safety of etimicin sulfate . Chin J Pharm Eco(中国药物经济学), 2012,(6): 41-44.

基金

十二五国家重大科技专项资助(2012ZX09303004-002)
PDF(1034 KB)

Accesses

Citation

Detail

段落导航
相关文章

/